Press Releases

Date Title and Summary Additional Formats
Toggle Summary AMICUS THERAPEUTICS' AT2101 GRANTED ORPHAN DRUG DESIGNATION FOR THE TREATMENT OF GAUCHER DISEASE
AMICUS THERAPEUTICS' AT2101 GRANTED ORPHAN DRUG DESIGNATION FOR THE TREATMENT OF GAUCHER DISEASE Cranbury, NJ, February 15, 2006 - Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-active pharmacological chaperones for the treatment of human genetic diseases, today
View HTML
Toggle Summary AMICUS THERAPEUTICS APPOINTS DAVID J. LOCKHART CHIEF SCIENTIFIC OFFICER
Dr. Lockhart Will Lead the Research Organization and Oversee the Advancement of Amicus' Pharmacological Chaperone Technology
View HTML
Toggle Summary AMICUS THERAPEUTICS TO PRESENT AT JPMORGAN HEALTHCARE CONFERENCE
AMICUS THERAPEUTICS TO PRESENT AT JPMORGAN HEALTHCARE CONFERENCE Cranbury, NJ, January 4, 2006 - Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-active pharmacological chaperones for the treatment of human genetic diseases, today announced that the company will
View HTML
Toggle Summary PHASE I CLINICAL STUDIES DEMONSTRATE SAFETY AND INITIAL "PROOF OF CONCEPT" FOR AMICUS' FABRY DISEASE DRUG
Lead Compound Based on Unique Pharmacological Chaperone Technology to Correct Misfolded Proteins Demonstrates Positive Biological Activity in Healthy Volunteers <br /><br />Amicus Initiates Phase II Clinical Program
View HTML
Toggle Summary AMICUS THERAPEUTICS RAISES $55 MILLION SERIES C FINANCING
New Funds to Accelerate Development of Unique Pharmacological Chaperones to Correct Misfolded Proteins <br /><br /> Pipeline Has the Potential to Transform Treatment of Human Genetic Diseases
View HTML
Toggle Summary AMICUS THERAPEUTICS APPOINTS JOHN F. CROWLEY CHAIRMAN AND CEO
New Executives Named to Management Team
View HTML
Toggle Summary AMICUS THERAPEUTICS INITIATES PHASE I TRIAL WITH LEAD COMPOUND AT1001 FOR THE TREATMENT OF FABRY DISEASE
AMICUS THERAPEUTICS INITIATES PHASE I TRIAL WITH LEAD COMPOUND AT1001 FOR THE TREATMENT OF FABRY DISEASE New Brunswick, NJ - Amicus Therapeutics, Inc., an emerging drug development company focused on the development of a novel therapeutic approach to the treatment of human genetic disorders, with
View HTML
Toggle Summary AMICUS THERAPEUTICS RAISES $31 MILLION IN SERIES B FINANCING
AMICUS THERAPEUTICS RAISES $31 MILLION IN SERIES B FINANCING New Brunswick, NJ - Amicus Therapeutics, Inc., an emerging drug development company focused on the development of a novel therapeutic approach to the treatment of human genetic disorders, with an initial focus on lysosomal storage
View HTML
Toggle Summary AMICUS THERAPEUTICS RECEIVES U.S. ORPHAN DRUG DESIGNATION FOR AT1001 IN THE TREATMENT OF FABRY DISEASE
AMICUS THERAPEUTICS RECEIVES U.S. ORPHAN DRUG DESIGNATION FOR AT1001 IN THE TREATMENT OF FABRY DISEASE New Brunswick, NJ - Amicus Therapeutics, Inc., an emerging drug development company focused on the development of a novel therapeutic approach to the treatment of human genetic disorders, with an
View HTML
Toggle Summary AMICUS THERAPEUTICS EXPANDS INTELLECTUAL PROPERTY ESTATE
Issuance of Fourth U.S. Patent Secures Company's Proprietary Position
View HTML